Dynavax Technologies (DVAX) Financials

$11.34 -0.10 (-0.87%)

As of 01:58 PM Eastern

Annual Income Statements for Dynavax Technologies

This table shows Dynavax Technologies' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-91	-107	-112	-95	-159	-156	-75	72	293	-6.39	27
Consolidated Net Income / (Loss)	-91	-107	-112	-95	-159	-153	-75	77	293	-6.39	27
Net Income / (Loss) Continuing Operations	-91	-107	-112	-95	-159	-153	-75	77	293	-6.39	27
Total Pre-Tax Income	-91	-105	-110	-95	-159	-153	-75	78	294	-4.37	31
Total Operating Income	-91	-105	-111	-96	-153	-135	-68	134	284	-37	-4.12
Total Gross Profit	11	4.05	11	0.33	-2.74	25	35	266	461	182	228
Total Revenue	11	4.05	11	0.33	8.20	35	47	439	723	232	277
Operating Revenue	11	4.05	11	0.33	8.20	35	47	439	723	232	277
Total Cost of Revenue	0.00	0.00	0.00	0.00	11	10	11	174	262	50	49
Operating Cost of Revenue	-	-	-	-	11	10	11	174	262	50	49
Total Operating Expenses	102	109	122	96	151	160	104	131	177	219	232
Selling, General & Admin Expense	17	22	37	27	65	75	79	100	131	153	170
Research & Development Expense	85	87	84	65	75	62	29	32	47	55	62
Other Operating Expenses / (Income)	-	-	-	-	-	-	-	0.00	0.00	12	0.00
Other Special Charges / (Income)	-	-	-	-	0.00	0.00	-6.85	-1.00	-1.00	-1.00	0.00
Total Other Income / (Expense), net	0.16	-0.37	0.76	1.34	-5.51	-18	-6.87	-57	11	33	35
Interest Expense	0.04	0.57	-	-	9.34	17	19	16	6.73	6.76	6.79
Interest & Investment Income	0.19	0.21	0.76	1.34	3.83	5.99	8.97	7.88	16	40	41
Other Income / (Expense), net	-	-	-	-	0.00	-6.77	3.23	-48	1.80	-0.15	0.29
Income Tax Expense	-	-	-	-	-	0.00	0.00	0.81	1.14	2.02	3.55
Net Income / (Loss) Attributable to Noncontrolling Interest	-	-	-	-	-	0.00	0.00	4.57	0.28	0.00	0.00
Basic Earnings per Share	($3.45)	($3.25)	($2.92)	($1.81)	($2.55)	($2.16)	($0.75)	$0.62	$2.32	($0.05)	$0.21
Weighted Average Basic Shares Outstanding	26.29M	32.88M	38.51M	52.61M	62.36M	72.02M	100.75M	116.26M	126.40M	128.73M	130.05M
Diluted Earnings per Share	($3.45)	($3.25)	($2.92)	($1.81)	($2.55)	($2.16)	($0.78)	$0.57	$1.97	($0.05)	$0.20
Weighted Average Diluted Shares Outstanding	26.29M	32.88M	38.51M	52.61M	62.36M	72.02M	101.50M	133.01M	150.80M	128.73M	133.34M
Weighted Average Basic & Diluted Shares Outstanding	26.29M	32.88M	38.51M	52.61M	62.36M	72.02M	113.26M	124.92M	127.69M	130.61M	124.07M

This table shows Dynavax Technologies' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	64	67	-24	3.43	14	0.22	-8.72	11	18	7.05
Consolidated Net Income / (Loss)	64	68	-24	3.43	14	0.22	-8.72	11	18	7.05
Net Income / (Loss) Continuing Operations	64	68	-24	3.43	14	0.22	-8.72	11	17	7.20
Total Pre-Tax Income	64	68	-24	4.21	14	1.00	-11	15	20	7.63
Total Operating Income	61	63	-30	-3.41	5.12	-8.49	-18	5.20	10	-1.63
Total Gross Profit	106	107	32	47	56	47	40	62	68	59
Total Revenue	168	184	47	60	70	56	51	74	81	72
Operating Revenue	168	184	47	60	70	56	51	74	81	72
Total Cost of Revenue	61	77	15	14	13	8.69	11	12	13	13
Operating Cost of Revenue	61	77	15	14	13	8.69	11	12	13	13
Total Operating Expenses	45	44	62	50	51	55	58	57	57	60
Selling, General & Admin Expense	32	31	37	37	38	41	44	42	43	42
Research & Development Expense	13	13	14	13	14	14	14	15	14	19
Total Other Income / (Expense), net	2.90	4.56	6.53	7.61	9.03	9.49	6.27	9.71	9.89	9.11
Interest Expense	1.69	1.68	1.69	1.69	1.69	1.69	1.70	1.70	1.70	1.70
Interest & Investment Income	4.59	6.35	6.60	7.38	8.46	17	9.47	9.20	9.38	13
Other Income / (Expense), net	0.00	-0.11	1.62	1.92	2.26	-5.95	-1.50	2.21	2.21	-2.62
Income Tax Expense	0.28	0.24	0.62	0.78	-0.15	0.78	-2.78	3.52	2.22	0.58
Basic Earnings per Share	$0.50	$0.54	($0.19)	$0.03	$0.11	-	($0.07)	$0.09	$0.13	$0.06
Weighted Average Basic Shares Outstanding	127.06M	126.40M	127.92M	128.63M	128.99M	128.73M	130.20M	130.92M	131.13M	130.05M
Diluted Earnings per Share	$0.43	$0.45	($0.19)	$0.03	$0.10	$0.01	($0.07)	$0.08	$0.12	$0.07
Weighted Average Diluted Shares Outstanding	151.54M	150.80M	127.92M	152.14M	154.20M	128.73M	130.20M	154.47M	154.81M	133.34M
Weighted Average Basic & Diluted Shares Outstanding	127.58M	127.69M	128.49M	128.80M	129.26M	130.61M	130.89M	131.04M	131.45M	124.07M

This table details how cash moves in and out of Dynavax Technologies' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	26	-4.70	-21	2.32	23	39	-7.79	404	-234	-52	-54
Net Cash From Operating Activities	-74	-93	-107	-78	-131	-121	-92	336	63	101	67
Net Cash From Continuing Operating Activities	-74	-93	-107	-78	-131	-87	-92	336	63	101	67
Net Income / (Loss) Continuing Operations	-91	-107	-112	-95	-159	-153	-75	77	293	-6.39	27
Consolidated Net Income / (Loss)	-91	-107	-112	-95	-159	-153	-75	77	293	-6.39	27
Depreciation Expense	1.40	1.37	2.26	3.24	3.62	8.94	4.27	4.30	3.81	4.34	4.63
Amortization Expense	0.88	0.66	0.18	1.00	9.30	11	5.60	3.23	-1.33	-14	-11
Non-Cash Adjustments To Reconcile Net Income	6.73	11	16	15	26	33	-23	74	201	51	57
Changes in Operating Assets and Liabilities, net	7.97	1.12	-13	-1.31	-12	13	-3.49	177	-434	65	-12
Net Cash From Investing Activities	91	-86	86	-109	55	-43	-27	14	-316	-154	-18
Net Cash From Continuing Investing Activities	91	-86	86	-109	55	-29	-27	14	-316	-154	-18
Purchase of Property, Plant & Equipment	-1.67	-6.97	-7.76	-0.67	-4.19	-22	-4.07	-9.48	-7.14	-4.10	-6.35
Purchase of Investments	-45	-209	-127	-228	-214	-215	-202	-165	-632	-637	-524
Sale of Property, Plant & Equipment	-	-	-	-	0.00	0.00	6.85	1.00	1.00	1.00	0.00
Sale and/or Maturity of Investments	137	130	221	120	284	202	179	188	322	486	512
Net Cash From Financing Activities	9.90	174	0.53	188	99	154	109	56	20	1.39	-102
Net Cash From Continuing Financing Activities	9.90	174	0.53	188	99	154	109	56	20	1.39	-102
Repurchase of Common Equity	-	-	-	-	-	-	-	-	0.00	0.00	-100
Issuance of Common Equity	0.29	184	0.62	186	0.59	67	109	47	9.89	1.54	1.76
Other Financing Activities, net	0.05	0.53	-0.08	1.61	-0.52	0.00	0.29	-21	9.64	-0.15	-3.78
Other Net Changes in Cash	-	-	-0.26	0.70	-	-	-	-1.43	-	0.32	-0.86
Cash Interest Paid	-	0.72	-	-	6.58	12	17	9.82	5.64	5.64	5.64
Cash Income Taxes Paid	-	-	-	-	-	0.00	0.00	1.31	2.21	2.01	4.59

This table details how cash moves in and out of Dynavax Technologies' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-51	3.45	-28	52	-72	-4.22	-18	-20	6.84	-23
Net Cash From Operating Activities	62	35	28	28	31	14	-17	11	19	53
Net Cash From Continuing Operating Activities	62	35	28	28	31	14	-17	11	19	53
Net Income / (Loss) Continuing Operations	64	68	-24	3.43	14	0.22	-8.72	11	18	7.05
Consolidated Net Income / (Loss)	64	68	-24	3.43	14	0.22	-8.72	11	18	7.05
Depreciation Expense	0.89	0.84	1.01	1.10	1.12	1.11	1.12	1.14	1.18	1.18
Amortization Expense	0.77	-1.60	-2.86	-3.07	-3.30	-4.40	-3.70	-3.09	-2.56	-1.77
Non-Cash Adjustments To Reconcile Net Income	65	39	23	8.55	10	9.19	20	11	6.78	20
Changes in Operating Assets and Liabilities, net	-68	-71	31	18	8.60	7.64	-25	-10	-3.53	27
Net Cash From Investing Activities	-119	-33	-52	25	-106	-20	2.83	-29	-15	23
Net Cash From Continuing Investing Activities	-119	-33	-52	25	-106	-20	2.83	-29	-15	23
Purchase of Property, Plant & Equipment	-1.28	-1.59	-1.28	-0.75	-0.35	-1.72	-0.75	-0.78	-1.35	-3.48
Purchase of Investments	-201	-118	-185	-74	-225	-153	-151	-175	-165	-33
Sale and/or Maturity of Investments	83	86	134	100	118	134	154	147	151	60
Net Cash From Financing Activities	8.06	0.15	-3.09	-0.29	2.99	1.78	-4.20	-1.42	2.48	-99
Net Cash From Continuing Financing Activities	8.06	0.15	-3.09	-0.29	2.99	1.78	-4.20	-1.42	2.48	-99
Other Financing Activities, net	7.34	0.15	-3.87	-0.29	2.24	1.78	-5.11	-1.42	1.62	1.13
Cash Interest Paid	-	2.82	0.00	2.82	-	2.82	0.00	2.82	-	2.82
Cash Income Taxes Paid	0.28	1.42	0.03	0.68	0.70	0.60	0.95	2.01	1.61	0.01

This table presents Dynavax Technologies' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	138	217	110	219	211	279	353	1,039	986	997	986
Total Current Assets	127	200	90	198	174	209	290	973	917	859	849
Cash & Equivalents	50	45	24	27	49	40	32	436	202	150	96
Short-Term Investments	73	151	57	165	96	111	133	110	422	592	618
Accounts Receivable	0.73	1.39	1.34	0.85	3.70	8.89	23	132	148	45	47
Inventories, net	-	-	-	0.31	19	41	64	61	59	53	70
Prepaid Expenses	4.06	2.43	6.84	3.70	6.10	7.38	39	233	86	19	18
Plant, Property, & Equipment, net	7.92	14	17	17	17	32	31	35	38	37	39
Total Noncurrent Assets	2.93	2.88	2.91	4.14	19	38	33	32	31	101	98
Goodwill	2.28	2.04	1.97	2.24	2.14	2.08	2.30	2.13	2.01	2.07	1.95
Other Noncurrent Operating Assets	0.02	0.23	0.33	1.27	4.98	34	30	29	29	99	96
Total Liabilities & Shareholders' Equity	138	217	110	219	211	279	353	1,039	986	997	986
Total Liabilities	38	30	20	19	148	271	295	817	405	375	389
Total Current Liabilities	20	29	20	19	38	53	77	556	150	62	79
Accounts Payable	1.16	3.43	3.80	4.54	5.28	9.28	3.31	2.60	3.21	5.25	9.06
Accrued Expenses	13	23	16	14	26	19	22	54	35	52	65
Other Current Liabilities	-	-	-	-	7.00	25	14	149	111	4.52	4.20
Total Noncurrent Liabilities	18	0.77	0.44	0.64	110	218	217	260	255	313	311
Long-Term Debt	9.56	-	-	-	101	179	180	220	222	223	224
Other Noncurrent Operating Liabilities	1.07	0.77	0.44	0.64	8.92	39	37	40	33	90	87
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	100	187	89	200	63	8.29	59	222	581	622	597
Total Preferred & Common Equity	100	187	89	200	63	8.29	59	222	581	622	597
Preferred Stock	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	100	187	89	200	63	8.29	59	222	581	622	597
Common Stock	695	890	905	1,108	1,131	1,230	1,352	1,442	1,511	1,555	1,505
Retained Earnings	-593	-700	-812	-907	-1,066	-1,219	-1,294	-1,217	-924	-931	-903
Accumulated Other Comprehensive Income / (Loss)	-1.67	-2.93	-3.62	-0.88	-2.02	-2.39	0.27	-2.27	-5.44	-2.11	-4.72

This table presents Dynavax Technologies' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	999	970	936	973	987	1,016	1,062
Total Current Assets	933	830	797	836	851	882	926
Cash & Equivalents	199	174	227	155	132	113	119
Short-Term Investments	388	478	455	566	592	623	645
Accounts Receivable	131	105	45	47	46	63	75
Inventories, net	103	58	53	49	62	62	62
Prepaid Expenses	113	16	17	19	20	21	25
Plant, Property, & Equipment, net	35	38	37	36	36	36	37
Total Noncurrent Assets	31	102	102	101	99	98	98
Goodwill	1.84	2.04	2.04	1.98	2.02	2.01	2.09
Other Noncurrent Operating Assets	29	99	99	99	97	96	96
Total Liabilities & Shareholders' Equity	999	970	936	973	987	1,016	1,062
Total Liabilities	499	406	359	368	368	373	381
Total Current Liabilities	244	92	45	54	56	62	70
Accounts Payable	3.05	7.30	3.25	3.12	2.43	4.56	7.09
Accrued Expenses	43	33	37	47	49	53	59
Other Current Liabilities	111	51	4.15	4.39	4.59	4.57	4.44
Total Noncurrent Liabilities	255	315	314	314	312	311	311
Long-Term Debt	221	222	222	222	223	223	224
Other Noncurrent Operating Liabilities	33	93	92	91	89	88	87
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	501	564	577	605	618	643	681
Total Preferred & Common Equity	501	564	577	605	618	643	681
Preferred Stock	-	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	501	564	577	605	618	643	681
Common Stock	1,502	1,516	1,528	1,542	1,562	1,576	1,591
Retained Earnings	-992	-949	-945	-931	-939	-928	-910
Accumulated Other Comprehensive Income / (Loss)	-9.26	-4.20	-5.37	-5.96	-4.37	-4.91	0.51

This table displays calculated financial ratios and metrics derived from Dynavax Technologies' official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-1.95%	-63.29%	172.67%	-97.04%	2,407.03%	329.60%	32.18%	844.00%	64.45%	-67.86%	19.36%
EBITDA Growth	-38.59%	-15.75%	-5.07%	15.25%	-53.00%	13.43%	54.52%	269.31%	207.55%	-116.14%	77.78%
EBIT Growth	-37.33%	-15.07%	-5.36%	13.28%	-59.70%	7.64%	54.00%	232.10%	231.56%	-113.03%	89.70%
NOPAT Growth	-37.33%	-15.07%	-5.36%	13.28%	-59.70%	12.05%	49.30%	378.07%	112.21%	-109.18%	85.92%
Net Income Growth	-35.97%	-17.72%	-5.29%	15.38%	-66.99%	3.96%	50.69%	201.96%	282.15%	-102.18%	527.44%
EPS Growth	9.92%	5.80%	10.15%	38.01%	-40.88%	15.29%	63.89%	173.08%	245.61%	-102.54%	500.00%
Operating Cash Flow Growth	-25.68%	-25.52%	-15.66%	27.59%	-69.38%	7.65%	23.92%	463.71%	-81.31%	60.35%	-33.86%
Free Cash Flow Firm Growth	-1.24%	-41.75%	-22.29%	28.89%	-75.95%	4.92%	23.84%	462.25%	-99.70%	5,314.81%	-116.06%
Invested Capital Growth	-253.71%	27.09%	174.41%	-1.64%	151.64%	100.33%	105.59%	-241.07%	272.50%	-42.50%	4.25%
Revenue Q/Q Growth	-4.91%	-28.22%	148.94%	-95.70%	182.59%	-7.97%	59.04%	66.50%	-1.44%	-35.69%	6.30%
EBITDA Q/Q Growth	-11.86%	-4.56%	6.92%	-9.09%	-6.84%	3.70%	23.46%	523.35%	-12.82%	-238.53%	55.55%
EBIT Q/Q Growth	-11.50%	-4.51%	6.44%	-9.74%	-7.07%	2.62%	22.32%	408.08%	-11.69%	-192.27%	72.70%
NOPAT Q/Q Growth	-11.50%	-4.51%	6.44%	-9.74%	-7.07%	7.27%	18.47%	354.03%	-6.20%	-176.74%	60.70%
Net Income Q/Q Growth	-11.33%	-4.48%	4.36%	-6.35%	-8.57%	2.06%	22.05%	299.08%	-9.85%	-110.45%	33.36%
EPS Q/Q Growth	-0.88%	-16.07%	4.26%	-16.77%	-9.44%	10.37%	40.91%	1,050.00%	-14.35%	-112.82%	42.86%
Operating Cash Flow Q/Q Growth	-7.31%	-5.69%	-4.32%	9.92%	-13.76%	8.05%	7.30%	68.36%	-57.70%	-17.40%	143.93%
Free Cash Flow Firm Q/Q Growth	-3.81%	-10.37%	-3.59%	10.86%	-12.85%	11.29%	4.11%	36.08%	-97.66%	-19.75%	81.55%
Invested Capital Q/Q Growth	-37.40%	4.63%	479.30%	-41.74%	7.84%	-13.56%	2.24%	18.39%	31.80%	-4.16%	-24.24%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	-33.37%	71.12%	75.49%	60.50%	63.73%	78.40%	82.17%
EBITDA Margin	-806.98%	-2,544.40%	-980.46%	-28,061.16%	-1,712.55%	-345.11%	-118.74%	21.30%	39.83%	-20.00%	-3.72%
Operating Margin	-827.69%	-2,594.40%	-1,002.51%	-29,359.33%	-1,870.20%	-382.87%	-146.87%	30.60%	39.23%	-15.94%	-1.49%
EBIT Margin	-827.69%	-2,594.40%	-1,002.51%	-29,359.33%	-1,870.20%	-402.09%	-139.94%	19.58%	39.48%	-16.01%	-1.38%
Profit (Net Income) Margin	-822.35%	-2,636.89%	-1,018.24%	-29,099.08%	-1,938.27%	-433.29%	-161.63%	17.46%	40.57%	-2.75%	9.85%
Tax Burden Percent	99.53%	101.28%	102.27%	100.51%	100.04%	100.00%	100.00%	98.96%	99.61%	146.30%	88.51%
Interest Burden Percent	99.83%	100.35%	99.32%	98.61%	103.59%	107.76%	115.50%	90.08%	103.15%	11.75%	-805.82%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.04%	0.39%	0.00%	11.49%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	-943.21%	-863.87%	-353.51%	-87.94%	0.00%	754.22%	-18.47%	-3.49%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	-922.84%	-820.49%	294.92%	-218.73%	0.00%	751.27%	-22.70%	-9.62%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	877.30%	742.86%	-74.21%	-136.72%	0.00%	-681.24%	17.41%	7.97%
Return on Equity (ROE)	-63.27%	-74.28%	-81.40%	-65.91%	-121.01%	-427.72%	-224.65%	54.59%	72.98%	-1.06%	4.48%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-1,313.11%	-941.55%	-950.12%	-420.33%	-157.04%	0.00%	0.52%	35.49%	-7.64%
Operating Return on Assets (OROA)	-53.26%	-59.21%	-67.85%	-58.46%	-71.37%	-57.81%	-20.60%	12.36%	28.18%	-3.75%	-0.39%
Return on Assets (ROA)	-52.91%	-60.18%	-68.92%	-57.94%	-73.96%	-62.29%	-23.80%	11.02%	28.95%	-0.64%	2.75%
Return on Common Equity (ROCE)	-63.27%	-74.28%	-81.40%	-65.91%	-121.01%	-427.72%	-224.65%	54.59%	72.98%	-1.06%	4.48%
Return on Equity Simple (ROE_SIMPLE)	-90.29%	-57.09%	-126.06%	-47.68%	-251.96%	-1,840.77%	-128.19%	34.50%	50.46%	-1.03%	4.58%
Net Operating Profit after Tax (NOPAT)	-64	-74	-77	-67	-107	-94	-48	133	282	-26	-3.65
NOPAT Margin	-579.38%	-1,816.08%	-701.76%	-20,551.53%	-1,309.14%	-268.01%	-102.81%	30.28%	39.08%	-11.16%	-1.32%
Net Nonoperating Expense Percent (NNEP)	-17.65%	-21.42%	-25.08%	-20.36%	-43.38%	-648.43%	130.79%	-36.24%	2.95%	4.23%	6.13%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	35.19%	-3.07%	-0.44%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	133.37%	28.88%	24.51%	39.50%	36.28%	21.60%	17.83%
SG&A Expenses to Revenue	157.51%	547.65%	337.38%	8,369.11%	790.07%	212.91%	170.26%	22.79%	18.18%	65.84%	61.45%
R&D to Revenue	766.68%	2,146.74%	765.13%	19,874.01%	914.26%	176.98%	61.45%	7.33%	6.45%	23.63%	22.20%
Operating Expenses to Revenue	927.69%	2,694.40%	1,102.51%	29,459.33%	1,836.83%	453.99%	222.36%	29.90%	24.49%	94.34%	83.65%
Earnings before Interest and Taxes (EBIT)	-91	-105	-111	-96	-153	-142	-65	86	285	-37	-3.83
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-89	-103	-108	-92	-140	-122	-55	94	288	-46	-10
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.41	4.96	1.71	5.68	9.10	57.87	8.35	7.59	2.34	2.90	2.81
Price to Tangible Book Value (P/TBV)	4.51	5.02	1.74	5.74	11.66	129.34	8.69	7.66	2.34	2.91	2.82
Price to Revenue (P/Rev)	40.18	229.22	13.78	3,465.29	69.97	13.62	10.53	3.84	1.88	7.78	6.05
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	23.39	4.64	0.00	61.47
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	4.27%	21.57%	0.00%	1.63%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	9.85	133.21	29.75	14.24	6.90	0.00	5.36	12.56	11.13
Enterprise Value to Revenue (EV/Rev)	29.93	180.80	6.41	2,878.58	64.52	14.40	10.85	3.10	1.32	5.54	4.29
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	14.56	3.32	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	15.83	3.35	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	10.24	3.38	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.06	15.22	12.80	17.87
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.40	1,037.87	25.85	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.10	0.00	0.00	0.00	1.60	21.54	3.06	0.99	0.38	0.36	0.38
Long-Term Debt to Equity	0.10	0.00	0.00	0.00	1.60	21.54	3.06	0.99	0.38	0.36	0.38
Financial Leverage	-1.06	-1.08	-1.01	-0.95	-0.91	-0.25	0.63	-1.11	-0.91	-0.77	-0.83
Leverage Ratio	1.20	1.23	1.18	1.14	1.64	6.87	9.44	4.95	2.52	1.65	1.63
Compound Leverage Factor	1.19	1.24	1.17	1.12	1.69	7.40	10.90	4.46	2.60	0.19	-13.11
Debt to Total Capital	8.69%	0.00%	0.00%	0.00%	61.53%	95.56%	75.39%	49.79%	27.61%	26.36%	27.28%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	8.69%	0.00%	0.00%	0.00%	61.53%	95.56%	75.39%	49.79%	27.61%	26.36%	27.28%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	91.31%	100.00%	100.00%	100.00%	38.47%	4.44%	24.61%	50.21%	72.39%	73.64%	72.72%
Debt to EBITDA	-0.11	0.00	0.00	0.00	-0.72	-1.47	-3.25	2.36	0.77	-4.79	-21.69
Net Debt to EBITDA	1.27	0.00	0.00	0.00	0.32	-0.23	-0.27	-3.48	-1.40	11.18	47.47
Long-Term Debt to EBITDA	-0.11	0.00	0.00	0.00	-0.72	-1.47	-3.25	2.36	0.77	-4.79	-21.69
Debt to NOPAT	-0.15	0.00	0.00	0.00	-0.94	-1.89	-3.76	1.66	0.78	-8.59	-61.36
Net Debt to NOPAT	1.77	0.00	0.00	0.00	0.42	-0.29	-0.31	-2.45	-1.43	20.05	134.30
Long-Term Debt to NOPAT	-0.15	0.00	0.00	0.00	-0.94	-1.89	-3.76	1.66	0.78	-8.59	-61.36
Altman Z-Score	-0.14	13.69	-8.38	29.08	-6.33	-5.93	-3.88	0.78	3.32	2.65	2.51
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.28	6.95	4.47	10.65	4.58	3.93	3.75	1.75	6.11	13.81	10.80
Quick Ratio	6.08	6.86	4.13	10.36	3.92	3.02	2.42	1.22	5.14	12.65	9.67
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-54	-77	-94	-67	-118	-112	-85	310	0.92	50	-8.00
Operating Cash Flow to CapEx	-4,423.40%	-1,327.96%	-1,380.06%	-11,587.15%	-3,135.92%	-541.28%	0.00%	3,958.10%	1,021.60%	3,239.79%	1,047.10%
Free Cash Flow to Firm to Interest Expense	-1,554.82	-134.86	0.00	0.00	-12.64	-6.61	-4.48	18.87	0.14	7.37	-1.18
Operating Cash Flow to Interest Expense	-2,106.80	-161.82	0.00	0.00	-14.06	-7.14	-4.84	20.45	9.32	14.88	9.79
Operating Cash Flow Less CapEx to Interest Expense	-2,154.43	-174.00	0.00	0.00	-14.51	-8.46	-4.69	19.93	8.40	14.42	8.85
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.06	0.02	0.07	0.00	0.04	0.14	0.15	0.63	0.71	0.23	0.28
Accounts Receivable Turnover	9.37	3.82	8.07	0.30	3.60	5.59	2.95	5.69	5.17	2.42	6.06
Inventory Turnover	0.00	0.00	0.00	0.00	1.13	0.34	0.22	2.78	4.34	0.89	0.80
Fixed Asset Turnover	1.33	0.37	0.71	0.02	0.49	1.44	1.49	13.40	19.90	6.20	7.27
Accounts Payable Turnover	0.00	0.00	0.00	0.00	2.23	1.40	1.81	58.72	90.23	11.87	6.91
Days Sales Outstanding (DSO)	38.94	95.58	45.22	1,225.60	101.47	65.24	123.68	64.15	70.54	150.89	60.19
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	322.70	1,082.84	1,679.78	131.45	84.08	410.12	455.26
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	163.86	261.16	201.37	6.22	4.05	30.76	52.80
Cash Conversion Cycle (CCC)	38.94	95.58	45.22	1,225.60	260.32	886.92	1,602.09	189.39	150.58	530.24	462.65
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-13	-9.66	7.18	7.07	18	36	73	-103	178	102	107
Invested Capital Turnover	-1.30	-0.35	-8.94	0.05	0.66	1.32	0.86	-29.22	19.30	1.66	2.65
Increase / (Decrease) in Invested Capital	-9.50	3.59	17	-0.12	11	18	38	-177	282	-76	4.35
Enterprise Value (EV)	330	732	71	941	529	507	505	1,362	955	1,287	1,189
Market Capitalization	443	928	152	1,133	574	480	490	1,688	1,358	1,807	1,679
Book Value per Share	$0.38	$4.87	$2.32	$3.29	$1.01	$0.10	$0.53	$1.85	$4.55	$4.81	$4.54
Tangible Book Value per Share	$0.37	$4.82	$2.26	$3.26	$0.78	$0.04	$0.51	$1.84	$4.54	$4.80	$4.53
Total Capital	110	187	89	200	164	187	239	443	803	845	821
Total Debt	9.56	0.00	0.00	0.00	101	179	180	220	222	223	224
Total Long-Term Debt	9.56	0.00	0.00	0.00	101	179	180	220	222	223	224
Net Debt	-113	-196	-81	-192	-45	28	15	-325	-403	-520	-490
Capital Expenditures (CapEx)	1.67	6.97	7.76	0.67	4.19	22	-2.78	8.48	6.14	3.10	6.35
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-15	-25	-12	-12	-9.21	4.55	48	-130	143	55	56
Debt-free Net Working Capital (DFNWC)	107	171	70	179	136	156	213	416	767	797	770
Net Working Capital (NWC)	107	171	70	179	136	156	213	416	767	797	770
Net Nonoperating Expense (NNE)	27	33	35	28	52	58	27	56	-11	-20	-31
Net Nonoperating Obligations (NNO)	-114	-197	-82	-192	-45	27	15	-326	-403	-520	-490
Total Depreciation and Amortization (D&A)	2.29	2.03	2.44	4.25	13	20	9.87	7.53	2.49	-9.28	-6.49
Debt-free, Cash-free Net Working Capital to Revenue	-140.45%	-616.40%	-107.33%	-3,799.39%	-112.28%	12.92%	102.18%	-29.54%	19.72%	23.52%	20.37%
Debt-free Net Working Capital to Revenue	971.34%	4,226.20%	629.93%	54,871.56%	1,662.98%	441.82%	456.71%	94.69%	106.12%	343.08%	277.84%
Net Working Capital to Revenue	971.34%	4,226.20%	629.93%	54,871.56%	1,662.98%	441.82%	456.71%	94.69%	106.12%	343.08%	277.84%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($3.45)	($3.25)	($2.92)	($1.81)	($2.55)	($2.16)	($0.75)	$0.62	$2.32	($0.05)	$0.21
Adjusted Weighted Average Basic Shares Outstanding	28.91M	38.48M	44.35M	61.68M	64.00M	86.19M	100.75M	116.26M	126.40M	128.73M	130.05M
Adjusted Diluted Earnings per Share	($3.45)	($3.25)	($2.92)	($1.81)	($2.55)	($2.16)	($0.78)	$0.57	$1.97	($0.05)	$0.20
Adjusted Weighted Average Diluted Shares Outstanding	28.91M	38.48M	44.35M	61.68M	64.00M	86.19M	101.50M	133.01M	150.80M	128.73M	133.34M
Adjusted Basic & Diluted Earnings per Share	($3.45)	($3.25)	($2.92)	($1.81)	($2.55)	($2.16)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	26.29M	32.88M	38.51M	52.61M	62.36M	72.02M	113.26M	124.92M	127.69M	130.61M	124.07M
Normalized Net Operating Profit after Tax (NOPAT)	-64	-74	-77	-65	-107	-85	-53	132	281	-27	-3.65
Normalized NOPAT Margin	-576.94%	-1,816.08%	-701.76%	-19,955.78%	-1,309.14%	-241.46%	-113.11%	30.06%	38.94%	-11.46%	-1.32%
Pre Tax Income Margin	-826.28%	-2,603.46%	-995.67%	-28,950.46%	-1,937.41%	-433.29%	-161.63%	17.64%	40.72%	-1.88%	11.13%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-2,608.89	-183.69	0.00	0.00	-16.42	-8.34	-3.42	5.24	42.38	-5.50	-0.56
NOPAT to Interest Expense	-1,826.22	-128.59	0.00	0.00	-11.49	-5.56	-2.51	8.11	41.95	-3.84	-0.54
EBIT Less CapEx to Interest Expense	-2,656.51	-195.88	0.00	0.00	-16.87	-9.66	-3.27	4.73	41.47	-5.96	-1.50
NOPAT Less CapEx to Interest Expense	-1,873.85	-140.77	0.00	0.00	-11.94	-6.88	-2.37	7.59	41.04	-4.30	-1.47
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	366.18%

This table displays calculated financial ratios and metrics derived from Dynavax Technologies' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	54.92%	-5.42%	-58.83%	-76.51%	-58.56%	-69.87%	8.24%	22.48%	15.99%	29.56%
EBITDA Growth	317.52%	-40.47%	-189.05%	-102.69%	-91.76%	-128.47%	28.29%	257.60%	110.09%	72.75%
EBIT Growth	313.07%	-37.47%	-187.63%	-101.16%	-87.99%	-122.92%	32.69%	599.19%	66.60%	70.59%
NOPAT Growth	443.46%	-22.06%	-168.83%	-102.18%	-91.54%	-102.97%	41.26%	242.98%	73.15%	19.16%
Net Income Growth	324.44%	-32.12%	-174.05%	-97.34%	-77.60%	-99.68%	64.16%	231.86%	23.10%	3,119.18%
EPS Growth	279.17%	-42.31%	-186.36%	-96.55%	-76.74%	-97.78%	63.16%	166.67%	20.00%	600.00%
Operating Cash Flow Growth	-7.02%	-71.00%	154.76%	68.43%	-49.43%	-60.61%	-160.38%	-61.80%	-37.46%	285.09%
Free Cash Flow Firm Growth	-195.80%	-184.97%	-306.02%	112.52%	116.67%	133.79%	102.04%	-275.98%	-175.11%	-107.93%
Invested Capital Growth	206.81%	272.50%	2,672.10%	-6.26%	-20.92%	-42.50%	-11.61%	10.97%	31.88%	4.25%
Revenue Q/Q Growth	-34.60%	9.99%	-74.57%	28.39%	15.38%	-20.02%	-8.64%	45.29%	9.26%	-10.66%
EBITDA Q/Q Growth	-50.84%	-1.26%	-148.93%	88.66%	250.36%	-441.27%	-38.85%	124.92%	100.44%	-144.26%
EBIT Q/Q Growth	-52.12%	2.66%	-145.42%	94.82%	597.30%	-295.86%	-54.75%	138.42%	65.97%	-134.58%
NOPAT Q/Q Growth	-52.10%	2.92%	-133.66%	86.88%	286.15%	-136.12%	-566.22%	131.92%	125.43%	-116.86%
Net Income Q/Q Growth	-50.44%	6.15%	-135.92%	114.10%	316.58%	-98.47%	-4,082.19%	230.56%	54.52%	-59.93%
EPS Q/Q Growth	-50.57%	4.65%	-142.22%	115.79%	233.33%	-90.00%	-800.00%	214.29%	50.00%	-41.67%
Operating Cash Flow Q/Q Growth	269.71%	-43.23%	-20.96%	1.54%	10.99%	-55.78%	-221.16%	164.23%	81.71%	172.31%
Free Cash Flow Firm Q/Q Growth	-394.98%	-8.94%	31.48%	103.39%	559.01%	120.76%	-95.86%	-392.29%	-181.27%	76.68%
Invested Capital Q/Q Growth	7.77%	31.80%	-25.13%	-11.86%	-9.09%	-4.16%	15.09%	10.67%	8.04%	-24.24%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	63.43%	58.00%	68.65%	77.53%	80.97%	84.37%	78.41%	83.76%	83.77%	81.38%
EBITDA Margin	37.60%	33.75%	-64.93%	-5.73%	7.47%	-31.89%	-43.02%	7.38%	13.54%	-6.71%
Operating Margin	36.60%	34.22%	-64.46%	-5.65%	7.36%	-15.27%	-34.99%	7.04%	12.50%	-2.27%
EBIT Margin	36.60%	34.16%	-61.01%	-2.46%	10.61%	-25.98%	-37.94%	10.03%	15.24%	-5.90%
Profit (Net Income) Margin	38.04%	36.71%	-51.85%	5.69%	20.56%	0.39%	-17.17%	15.43%	21.82%	9.79%
Tax Burden Percent	99.56%	99.65%	102.60%	81.55%	101.04%	21.99%	75.85%	76.39%	88.78%	92.42%
Interest Burden Percent	104.39%	107.84%	82.84%	-283.68%	191.81%	-6.90%	59.66%	201.35%	161.29%	-179.52%
Effective Tax Rate	0.44%	0.35%	0.00%	18.45%	-1.04%	78.01%	0.00%	23.61%	11.22%	7.58%
Return on Invested Capital (ROIC)	6,197.00%	658.11%	-428.01%	-17.42%	22.19%	-5.56%	-46.02%	10.83%	23.36%	-5.55%
ROIC Less NNEP Spread (ROIC-NNEP)	6,196.04%	656.79%	-427.13%	-19.06%	20.07%	-6.01%	-46.82%	9.30%	21.69%	-7.25%
Return on Net Nonoperating Assets (RNNOA)	-6,101.99%	-595.56%	357.76%	14.43%	-15.68%	4.61%	36.86%	-7.41%	-17.51%	6.00%
Return on Equity (ROE)	95.01%	62.55%	-70.25%	-2.99%	6.51%	-0.95%	-9.15%	3.42%	5.85%	0.45%
Cash Return on Invested Capital (CROIC)	29.08%	0.52%	133.48%	79.97%	51.27%	35.49%	-10.61%	-22.30%	-34.98%	-7.64%
Operating Return on Assets (OROA)	27.97%	24.38%	-40.42%	-1.15%	3.89%	-6.09%	-9.16%	2.57%	3.91%	-1.65%
Return on Assets (ROA)	29.07%	26.20%	-34.36%	2.67%	7.53%	0.09%	-4.15%	3.95%	5.59%	2.74%
Return on Common Equity (ROCE)	95.01%	62.55%	-70.25%	-2.99%	6.51%	-0.95%	-9.15%	3.42%	5.85%	0.45%
Return on Equity Simple (ROE_SIMPLE)	64.97%	0.00%	41.86%	19.17%	10.10%	0.00%	1.49%	2.67%	3.01%	0.00%
Net Operating Profit after Tax (NOPAT)	61	63	-21	-2.78	5.17	-1.87	-12	3.97	8.95	-1.51
NOPAT Margin	36.44%	34.10%	-45.12%	-4.61%	7.44%	-3.36%	-24.49%	5.38%	11.10%	-2.10%
Net Nonoperating Expense Percent (NNEP)	0.96%	1.32%	-0.89%	1.64%	2.11%	0.45%	0.80%	1.53%	1.66%	1.70%
Return On Investment Capital (ROIC_SIMPLE)	-	7.84%	-	-	-	-0.22%	-	-	-	-0.18%
Cost of Revenue to Revenue	36.57%	42.00%	31.35%	22.47%	19.03%	15.63%	21.59%	16.24%	16.23%	18.62%
SG&A Expenses to Revenue	19.10%	16.81%	77.88%	61.53%	54.74%	74.25%	86.76%	56.46%	53.41%	57.73%
R&D to Revenue	7.73%	6.97%	28.99%	21.65%	20.31%	25.40%	26.64%	20.26%	17.86%	25.92%
Operating Expenses to Revenue	26.83%	23.78%	133.11%	83.18%	73.61%	99.64%	113.39%	76.72%	71.27%	83.65%
Earnings before Interest and Taxes (EBIT)	61	63	-29	-1.48	7.38	-14	-19	7.40	12	-4.25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	63	62	-30	-3.46	5.20	-18	-22	5.45	11	-4.83
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.64	2.34	2.22	2.88	3.14	2.90	2.59	2.29	2.14	2.81
Price to Tangible Book Value (P/TBV)	2.65	2.34	2.23	2.89	3.16	2.91	2.60	2.29	2.15	2.82
Price to Revenue (P/Rev)	1.80	1.88	1.91	3.61	5.27	7.78	6.79	5.89	5.60	6.05
Price to Earnings (P/E)	4.12	4.64	5.31	15.04	31.27	0.00	173.95	85.57	71.29	61.47
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	24.28%	21.57%	18.82%	6.65%	3.20%	0.00%	0.57%	1.17%	1.40%	1.63%
Enterprise Value to Invested Capital (EV/IC)	7.06	5.36	6.16	10.21	13.14	12.56	9.36	7.34	6.52	11.13
Enterprise Value to Revenue (EV/Rev)	1.30	1.32	1.25	2.61	3.89	5.54	4.67	3.84	3.53	4.29
Enterprise Value to EBITDA (EV/EBITDA)	2.89	3.32	3.69	13.14	41.87	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	2.96	3.35	3.67	12.73	34.85	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	3.17	3.38	3.72	13.44	41.58	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	6.44	15.22	5.84	7.89	11.54	12.80	19.61	24.60	33.72	17.87
Enterprise Value to Free Cash Flow (EV/FCFF)	24.29	1,037.87	8.92	12.35	22.63	25.85	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.44	0.38	0.39	0.38	0.37	0.36	0.36	0.35	0.33	0.38
Long-Term Debt to Equity	0.44	0.38	0.39	0.38	0.37	0.36	0.36	0.35	0.33	0.38
Financial Leverage	-0.98	-0.91	-0.84	-0.76	-0.78	-0.77	-0.79	-0.80	-0.81	-0.83
Leverage Ratio	3.38	2.52	2.32	1.96	1.78	1.65	1.65	1.60	1.58	1.63
Compound Leverage Factor	3.53	2.72	1.93	-5.56	3.42	-0.11	0.99	3.22	2.55	-2.92
Debt to Total Capital	30.66%	27.61%	28.24%	27.79%	26.88%	26.36%	26.50%	25.78%	24.70%	27.28%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	30.66%	27.61%	28.24%	27.79%	26.88%	26.36%	26.50%	25.78%	24.70%	27.28%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	69.34%	72.39%	71.76%	72.21%	73.12%	73.64%	73.50%	74.22%	75.30%	72.72%
Debt to EBITDA	0.67	0.77	0.99	2.43	6.63	-4.79	-5.89	-7.72	-9.63	-21.69
Net Debt to EBITDA	-1.11	-1.40	-1.93	-5.03	-14.85	11.18	13.23	17.70	23.27	47.47
Long-Term Debt to EBITDA	0.67	0.77	0.99	2.43	6.63	-4.79	-5.89	-7.72	-9.63	-21.69
Debt to NOPAT	0.74	0.78	1.00	2.49	6.58	-8.59	-7.73	-15.12	-24.08	-61.36
Net Debt to NOPAT	-1.21	-1.43	-1.95	-5.14	-14.74	20.05	17.36	34.70	58.22	134.30
Long-Term Debt to NOPAT	0.74	0.78	1.00	2.49	6.58	-8.59	-7.73	-15.12	-24.08	-61.36
Altman Z-Score	1.96	2.58	1.97	2.81	3.12	2.73	2.42	2.32	2.35	2.51
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.82	6.11	9.07	17.78	15.40	13.81	15.20	14.18	13.23	10.80
Quick Ratio	2.94	5.14	8.27	16.20	14.14	12.65	13.74	12.84	11.98	9.67
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-201	-219	-150	5.08	33	74	3.06	-8.93	-25	-5.86
Operating Cash Flow to CapEx	4,805.62%	2,202.14%	2,152.92%	3,734.49%	8,970.89%	798.96%	-2,226.84%	1,375.22%	1,446.29%	1,524.18%
Free Cash Flow to Firm to Interest Expense	-119.08	-129.80	-88.84	3.01	19.79	43.65	1.80	-5.26	-14.79	-3.44
Operating Cash Flow to Interest Expense	36.53	20.75	16.38	16.61	18.41	8.14	-9.84	6.31	11.46	31.15
Operating Cash Flow Less CapEx to Interest Expense	35.77	19.81	15.62	16.17	18.20	7.12	-10.28	5.85	10.67	29.10
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.76	0.71	0.66	0.47	0.37	0.23	0.24	0.26	0.26	0.28
Accounts Receivable Turnover	4.42	5.17	5.42	4.18	4.06	2.42	3.13	4.62	4.27	6.06
Inventory Turnover	3.04	4.34	3.47	2.63	1.57	0.89	0.78	0.78	0.80	0.80
Fixed Asset Turnover	21.07	19.90	17.58	12.46	10.10	6.20	6.33	6.79	7.09	7.27
Accounts Payable Turnover	77.84	90.23	17.24	40.72	38.56	11.87	9.54	11.50	8.76	6.91
Days Sales Outstanding (DSO)	82.50	70.54	67.31	87.24	89.93	150.89	116.71	78.92	85.47	60.19
Days Inventory Outstanding (DIO)	119.87	84.08	105.33	138.80	233.21	410.12	469.80	469.99	456.27	455.26
Days Payable Outstanding (DPO)	4.69	4.05	21.18	8.96	9.47	30.76	38.24	31.73	41.66	52.80
Cash Conversion Cycle (CCC)	197.68	150.58	151.46	217.07	313.68	530.24	548.27	517.18	500.08	462.65
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	135	178	133	118	107	102	118	131	141	107
Invested Capital Turnover	170.05	19.30	9.49	3.78	2.98	1.66	1.88	2.01	2.10	2.65
Increase / (Decrease) in Invested Capital	262	282	129	-7.85	-28	-76	-15	13	34	4.35
Enterprise Value (EV)	955	955	823	1,201	1,404	1,287	1,104	958	919	1,189
Market Capitalization	1,320	1,358	1,253	1,660	1,902	1,807	1,604	1,470	1,460	1,679
Book Value per Share	$3.96	$4.55	$4.42	$4.49	$4.70	$4.81	$4.75	$4.91	$5.20	$4.54
Tangible Book Value per Share	$3.94	$4.54	$4.40	$4.48	$4.68	$4.80	$4.73	$4.90	$5.18	$4.53
Total Capital	722	803	786	799	827	845	841	866	905	821
Total Debt	221	222	222	222	222	223	223	223	224	224
Total Long-Term Debt	221	222	222	222	222	223	223	223	224	224
Net Debt	-365	-403	-430	-459	-498	-520	-501	-512	-540	-490
Capital Expenditures (CapEx)	1.28	1.59	1.28	0.75	0.35	1.72	0.75	0.78	1.35	3.48
Debt-free, Cash-free Net Working Capital (DFCFNWC)	102	143	87	71	61	55	72	84	92	56
Debt-free Net Working Capital (DFNWC)	689	767	739	753	781	797	795	820	856	770
Net Working Capital (NWC)	689	767	739	753	781	797	795	820	856	770
Net Nonoperating Expense (NNE)	-2.68	-4.82	3.16	-6.21	-9.12	-2.09	-3.72	-7.42	-8.64	-8.56
Net Nonoperating Obligations (NNO)	-365	-403	-430	-460	-498	-520	-501	-512	-540	-490
Total Depreciation and Amortization (D&A)	1.66	-0.76	-1.84	-1.97	-2.18	-3.28	-2.58	-1.96	-1.37	-0.58
Debt-free, Cash-free Net Working Capital to Revenue	13.96%	19.72%	13.22%	15.47%	16.89%	23.52%	30.38%	33.72%	35.36%	20.37%
Debt-free Net Working Capital to Revenue	93.95%	106.12%	112.66%	163.82%	216.35%	343.08%	336.77%	328.33%	328.29%	277.84%
Net Working Capital to Revenue	93.95%	106.12%	112.66%	163.82%	216.35%	343.08%	336.77%	328.33%	328.29%	277.84%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.50	$0.54	($0.19)	$0.03	$0.11	$0.00	($0.07)	$0.09	$0.13	$0.06
Adjusted Weighted Average Basic Shares Outstanding	127.06M	126.40M	127.92M	128.63M	128.99M	128.73M	130.20M	130.92M	131.13M	130.05M
Adjusted Diluted Earnings per Share	$0.43	$0.45	($0.19)	$0.03	$0.10	$0.01	($0.07)	$0.08	$0.12	$0.07
Adjusted Weighted Average Diluted Shares Outstanding	151.54M	150.80M	127.92M	152.14M	154.20M	128.73M	130.20M	154.47M	154.81M	133.34M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	127.58M	127.69M	128.49M	128.80M	129.26M	130.61M	130.89M	131.04M	131.45M	124.07M
Normalized Net Operating Profit after Tax (NOPAT)	61	63	-21	-2.78	2.88	-5.94	-12	3.97	8.95	-1.51
Normalized NOPAT Margin	36.44%	34.10%	-45.12%	-4.61%	4.14%	-10.69%	-24.49%	5.38%	11.10%	-2.10%
Pre Tax Income Margin	38.21%	36.84%	-50.54%	6.98%	20.35%	1.79%	-22.64%	20.20%	24.58%	10.59%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	36.44	37.43	-16.98	-0.88	4.36	-8.54	-11.37	4.36	7.23	-2.50
NOPAT to Interest Expense	36.28	37.36	-12.56	-1.65	3.06	-1.10	-7.34	2.34	5.27	-0.89
EBIT Less CapEx to Interest Expense	35.68	36.49	-17.74	-1.32	4.16	-9.56	-11.81	3.90	6.44	-4.54
NOPAT Less CapEx to Interest Expense	35.52	36.42	-13.32	-2.09	2.85	-2.12	-7.78	1.88	4.48	-2.93
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	366.18%

Frequently Asked Questions About Dynavax Technologies' Financials

When does Dynavax Technologies's financial year end?

According to the most recent income statement we have on file, Dynavax Technologies' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Dynavax Technologies' net income changed over the last 10 years?

Dynavax Technologies' net income appears to be on a downward trend, with a most recent value of $27.31 million in 2024, falling from -$90.72 million in 2014. The previous period was -$6.39 million in 2023.

What is Dynavax Technologies's operating income?

Dynavax Technologies's total operating income in 2024 was -$4.12 million, based on the following breakdown:

Total Gross Profit: $227.80 million
Total Operating Expenses: $231.92 million

How has Dynavax Technologies revenue changed over the last 10 years?

Over the last 10 years, Dynavax Technologies' total revenue changed from $11.03 million in 2014 to $277.25 million in 2024, a change of 2,413.1%.

How much debt does Dynavax Technologies have?

Dynavax Technologies' total liabilities were at $389.46 million at the end of 2024, a 3.8% increase from 2023, and a 930.1% increase since 2014.

How much cash does Dynavax Technologies have?

In the past 10 years, Dynavax Technologies' cash and equivalents has ranged from $24.29 million in 2016 to $436.19 million in 2021, and is currently $95.88 million as of their latest financial filing in 2024.

How has Dynavax Technologies' book value per share changed over the last 10 years?

Over the last 10 years, Dynavax Technologies' book value per share changed from 0.38 in 2014 to 4.54 in 2024, a change of 1,087.9%.

Remove Ads

Related Companies

This page (NASDAQ:DVAX) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dynavax Technologies (DVAX) Financials

Frequently Asked Questions About Dynavax Technologies' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dynavax Technologies (DVAX) Financials

Annual Income Statements for Dynavax Technologies

Quarterly Income Statements for Dynavax Technologies

Annual Cash Flow Statements for Dynavax Technologies

Quarterly Cash Flow Statements for Dynavax Technologies

Annual Balance Sheets for Dynavax Technologies

Quarterly Balance Sheets for Dynavax Technologies

Annual Metrics and Ratios for Dynavax Technologies

Quarterly Metrics and Ratios for Dynavax Technologies

Frequently Asked Questions About Dynavax Technologies' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools